Search research articles
Contact Us
Filters
Showing results (191-200 of 227) with videos related to
Page
of 23
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 7, 2011
Small cell lung cancer
Gregory P Kalemkerian, Wallace Akerley, Paul Bogner, et al.
Biorxiv : the Preprint Server for Biology
|
February 7, 2023
Loss of the endocytic tumor suppressor HD-PTP phenocopies LKB1 and promotes RAS-driven oncogenesis
Chang-Soo Seong, Chunzi Huang, Austin C Boese, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 12, 2013
Small cell lung cancer
Gregory P Kalemkerian, Wallace Akerley, Paul Bogner, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 2, 2008
Non-small cell lung cancer
David S Ettinger, Wallace Akerley, Gerold Bepler, et al.
The Lancet. Oncology
|
October 3, 2024
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial
Jürgen Wolf, Maximilian Hochmair, Ji-Youn Han, et al.
British Journal of Cancer
|
February 13, 2001
Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine
K A Jaeckle, S Phuphanich, M J Bent, et al.
The New England Journal of Medicine
|
June 8, 2010
Improved survival with ipilimumab in patients with metastatic melanoma
F Stephen Hodi, Steven J O'Day, David F McDermott, et al.
Oncoimmunology
|
January 3, 2024
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies
Chia-Chi Lin, Elena Garralda, Patrick Schöffski, et al.
Journal for Immunotherapy of Cancer
|
February 26, 2022
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
Patrick Schöffski, Daniel S W Tan, Miguel Martín, et al.
Nature Medicine
|
June 1, 2026
SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial
Lauren Averett Byers, Byoung Chul Cho, Alissa J Cooper, et al.
Page
of 23
Search research articles
Search
Showing results (191-200 of 227) with videos related to
Sort By:
Page
of 23
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 7, 2011
Small cell lung cancer
Gregory P Kalemkerian, Wallace Akerley, Paul Bogner, et al.
Biorxiv : the Preprint Server for Biology
|
February 7, 2023
Loss of the endocytic tumor suppressor HD-PTP phenocopies LKB1 and promotes RAS-driven oncogenesis
Chang-Soo Seong, Chunzi Huang, Austin C Boese, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 12, 2013
Small cell lung cancer
Gregory P Kalemkerian, Wallace Akerley, Paul Bogner, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 2, 2008
Non-small cell lung cancer
David S Ettinger, Wallace Akerley, Gerold Bepler, et al.
The Lancet. Oncology
|
October 3, 2024
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial
Jürgen Wolf, Maximilian Hochmair, Ji-Youn Han, et al.
British Journal of Cancer
|
February 13, 2001
Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine
K A Jaeckle, S Phuphanich, M J Bent, et al.
The New England Journal of Medicine
|
June 8, 2010
Improved survival with ipilimumab in patients with metastatic melanoma
F Stephen Hodi, Steven J O'Day, David F McDermott, et al.
Oncoimmunology
|
January 3, 2024
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies
Chia-Chi Lin, Elena Garralda, Patrick Schöffski, et al.
Journal for Immunotherapy of Cancer
|
February 26, 2022
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
Patrick Schöffski, Daniel S W Tan, Miguel Martín, et al.
Nature Medicine
|
June 1, 2026
SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial
Lauren Averett Byers, Byoung Chul Cho, Alissa J Cooper, et al.
Page
of 23